Glenmark Pharmaceuticals reported FY26 consolidated revenue of ₹16,983 crore, up 27.5% year-on-year, with EBITDA margin at 26.9%. During the year, the company entered into a licensing agreement with AbbVie for ISB 2001, securing a $700 million upfront payment and a potential deal value of $1.925 billion. The company also expanded its oncology portfolio, advanced its respiratory business in the US, and continued the global rollout of Ryaltris.